Nanodrugs: Pharmacokinetics and Safety

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2014 Mar 5

PMID 24591825

Citations 93

Authors

Satomi Onoue

Shizuo Yamada

Hak-Kim Chan

Affiliations

Soon will be listed here.

Abstract

To date, various nanodrug systems have been developed for different routes of administration, which include dendrimers, nanocrystals, emulsions, liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles. Nanodrug systems have been employed to improve the efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic profile of pharmaceutical substances. In particular, functionalized nanodrug systems can offer enhanced bioavailability of orally taken drugs, prolonged half-life of injected drugs (by reducing immunogenicity), and targeted delivery to specific tissues. Thus, nanodrug systems might lower the frequency of administration while providing maximized pharmacological effects and minimized systemic side effects, possibly leading to better therapeutic compliance and clinical outcomes. In spite of these attractive pharmacokinetic advantages, recent attention has been drawn to the toxic potential of nanodrugs since they often exhibit in vitro and in vivo cytotoxicity, oxidative stress, inflammation, and genotoxicity. A better understanding of the pharmacokinetic and safety characteristics of nanodrugs and the limitations of each delivery option is necessary for the further development of efficacious nanodrugs with high therapeutic potential and a wide safety margin. This review highlights the recent progress in nanodrug system development, with a focus on the pharmacokinetic advantages and safety challenges.

Citing Articles

Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics.

Chen A, Gong Y, Wu S, Du Y, Liu Z, Jiang Y J Nanobiotechnology. 2025; 23(1):72.

PMID: 39893419 PMC: 11786591. DOI: 10.1186/s12951-025-03141-3.

Injectable Senolytic Hydrogel Depot for the Clearance of Senescent Cells.

Garau Paganella L, Bovone G, Cuni F, Labouesse C, Cui Y, Giampietro C Biomacromolecules. 2025; 26(2):814-824.

PMID: 39783796 PMC: 11815846. DOI: 10.1021/acs.biomac.4c00851.

Chlorogenic Acid-Cucurbit[n]uril Nanocomplex Delivery System: Synthesis and Evaluations for Potential Applications in Osteoporosis Medication.

Jiang Y, Qi H, Wang M, Chen K, Chen C, Xie H Int J Nanomedicine. 2024; 19:11577-11592.

PMID: 39539971 PMC: 11559225. DOI: 10.2147/IJN.S485581.

Optimizing gefitinib nanoliposomes by Box-Behnken design and coating with chitosan: A sequential approach for enhanced drug delivery.

Rohilla S, Awasthi R, Rohilla A, Singh S, Chellappan D, Dua K ADMET DMPK. 2024; 12(4):657-677.

PMID: 39473624 PMC: 11517515. DOI: 10.5599/admet.2366.

Docetaxel-tethered di-Carboxylic Acid Derivatised Fullerenes: A Promising Drug Delivery Approach for Breast Cancer.

Misra C, Kaur J, Kumar M, Kaushik L, Chitkara D, Preet S AAPS PharmSciTech. 2024; 25(7):233.

PMID: 39358486 DOI: 10.1208/s12249-024-02955-y.

References

Kaminskas L, Kelly B, McLeod V, Sberna G, Boyd B, Owen D . Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. Mol Pharm. 2010; 8(2):338-49. DOI: 10.1021/mp1001872. View

Feldman E, Kolitz J, Trang J, Liboiron B, Swenson C, Chiarella M . Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012; 36(10):1283-9. DOI: 10.1016/j.leukres.2012.07.006. View

Ai J, Biazar E, Jafarpour M, Montazeri M, Majdi A, Aminifard S . Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine. 2011; 6:1117-27. PMC: 3118686. DOI: 10.2147/IJN.S16603. View

Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N . Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine. 2013; 8:495-503. PMC: 3576887. DOI: 10.2147/IJN.S30725. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X . Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm. 2006; 327(1-2):153-9. DOI: 10.1016/j.ijpharm.2006.07.026. View

Fetterly G, Straubinger R . Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci. 2004; 5(4):E32. PMC: 2750994. DOI: 10.1208/ps050432. View

Pathak P, Nagarsenker M . Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech. 2009; 10(3):985-92. PMC: 2802165. DOI: 10.1208/s12249-009-9287-1. View

Kabanov A, Alakhov V . Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002; 19(1):1-72. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i1.10. View

10.

Larsen A, Ohlsson A, Polentarutti B, Barker R, Phillips A, Abu-Rmaileh R . Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2012; 48(1-2):339-50. DOI: 10.1016/j.ejps.2012.11.004. View

11.

Thomas N, Holm R, Garmer M, Karlsson J, Mullertz A, Rades T . Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J. 2012; 15(1):219-27. PMC: 3535117. DOI: 10.1208/s12248-012-9433-7. View

12.

Jain A, Jain S . In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci. 2008; 35(5):404-16. DOI: 10.1016/j.ejps.2008.08.008. View

13.

des Rieux A, Fievez V, Garinot M, Schneider Y, Preat V . Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006; 116(1):1-27. DOI: 10.1016/j.jconrel.2006.08.013. View

14.

Kawakami S, Yamamura K, Mukai T, Nishida K, Nakamura J, Sakaeda T . Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J Pharm Pharmacol. 2001; 53(8):1157-61. DOI: 10.1211/0022357011776423. View

15.

Manvelian G, Daniels S, Altman R . A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. Postgrad Med. 2012; 124(4):197-205. DOI: 10.3810/pgm.2012.07.2580. View

16.

Uchegbu I, Siew A . Nanomedicines and nanodiagnostics come of age. J Pharm Sci. 2012; 102(2):305-10. DOI: 10.1002/jps.23377. View

17.

Chan H, Kwok P . Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev. 2011; 63(6):406-16. DOI: 10.1016/j.addr.2011.03.011. View

18.

Reddy L, Sharma R, Chuttani K, Mishra A, Murthy R . Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2005; 6(3):e23. PMC: 2751248. DOI: 10.1208/aapsj060323. View

19.

Francis M, Cristea M, Winnik F . Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules. 2005; 6(5):2462-7. DOI: 10.1021/bm0503165. View

20.

Kaminskas L, McLeod V, Kelly B, Sberna G, Boyd B, Williamson M . A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine. 2011; 8(1):103-11. DOI: 10.1016/j.nano.2011.05.013. View